Cubist is paying $5 million up front and $5 million in R&D funding to advance preclinical candidates.
Cubist Pharmaceuticals is paying $5 million up front to collaborate with Hydra Biosciences on the development of ion channel drugs for pain management. Cubist will support Hydra’s internal development R&D programs with another $5 million over two years.
Hydra’s focus has been on compounds that target the TRPA1 receptor, which is believed to have an important role in pain management. The partnership will build on existing preclinical data and pharmacology studies.
Under the terms of the agreement, Hydra is eligible for development milestones and royalties on product sales.